CARsgen Therapeutics Holdings Limited (HK:2171), a China-based company focused on developing innovative CAR T-cell therapies, on Monday announced encouraging clinical data for its allogeneic CAR-T candidates CT0596 and CT1190B, developed on the company's THANK-u Plus platform.

Both products demonstrated favourable safety profiles and early signs of efficacy in patients with relapsed or refractory haematologic malignancies.

In an investigator-initiated trial of CT0596 for relapsed or refractory multiple myeloma, five of eight treated patients achieved partial response or better, including three complete or stringent complete responses, all of whom received full lymphodepletion. CAR-T cell expansion was observed in all eight patients. No dose-limiting toxicities, treatment discontinuations, or deaths occurred, and only mild cytokine release syndrome was observed.

For relapsed or refractory non-Hodgkin's lymphoma, CT1190B demonstrated strong clinical activity, with an overall response rate of 83.3% among evaluable patients. All three follicular lymphoma patients achieved complete response, including those previously treated with CAR-T and bispecific antibody therapies. No cases of neurotoxicity or graft-versus-host disease were reported.

CARsgen plans to advance CT0596 toward an Investigational New Drug application in the second half of 2025 and continue development of CT1190B in B-cell malignancies and autoimmune diseases.